NIUS Niusule Biotech Corp. featured news, full reports, and detailed charts
Niusule Biotech Corp. (NIUS/NIUS.OB) Wrap Up:
Niusule Biotech Corp. engages in the wholesale and retail of health food products in the Peoples Republic of China. It sells PlantFusion that contains a proprietary enzyme blend, which supports easy digestion and absorption; and Gummy Bears, a multivitamin formula and a formula fortified with Vitamin D, Calcium, and Phosphorus. The company was founded in 2008 and is based in Carson City, Nevada.Founded in 2008
Niusule Biotech Corp. (NIUS:OTC Bulletin Board Market)
LAST $0.60 USD
CHANGE TODAY 0.00 0.00%
VOLUME 0.0
As of November 9, 2009 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Niusule Biotech Corp. (NIUS)
|
OPEN
--
|
PREVIOUS CLOSE
$0.60
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
02/6/09 - $0.68
|
52 WEEK LOW
10/9/09 - $0.22
|
|
|
MARKET CAP
30.7M
|
AVERAGE VOLUME 3 mo
300.0
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
51.2M
|
|
|
NIUS Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
NIUS Top Compensated Officers
Ms. Qinghua Hu
Chairman of the Board and Chief Executive Off...
Age: 41
Total Annual Compensation: $36.0K
Executives, Board Directors
Compensation as of Fiscal Year 2009.
Key developments for Niusule Biotech Corp. (NIUS)
Niusule Biotech Corp. Provides Earnings Guidance for the Calendar Year Ending December 31, 2010
11/18/2009
Niusule Biotech Corp. provided earnings guidance for the calendar year ending December 31, 2010. For the period, the company expect based on current trends and planned expansion of its retail distribution network, the company is now forecasting that revenue for the calender year 2010 is expected to be approximately $10 million. The Company estimates gross margin to be in the range of 70%-75% with net income of $2.5 to $3 million for calender year 2010.
Niusule Biotech Corp. Enters into One Year Distribution Contract with Hainan Qi Zheng Pharmaceutical Co., Ltd
11/18/2009
Niusule Biotech Corp. announced that the company's popular Gummy Bear products will be distributed in Shanghai, the city in China. The Company has entered into a one year distribution contract with Hainan Qi Zheng Pharmaceutical Co. Ltd. Hainan Qi Zheng will distribute Niusule's Gummy Bear products across Shanghai through drugstores, shopping malls, and children stores. Under the contract, Hainan Qi Zheng is responsible for distributing Niusule's Gummy Bear products in Shanghai to 100 retail outlets by December 10, 2009 and to 280 retail outlets by end of 2010. Niusule will advertise its products in Shanghai and estimates advertising expense to be 5% of the total wholesale revenues from Hainan Qi Zheng. According to Hainan Qi Zheng, the order value is expected to reach $5.0 million in the calendar year 2010.
Niusule Biotech Corp. Enters Two Year Distribution Contract with Hangzhou Rong Sen Food Co., Ltd
11/17/2009
Niusule Biotech Corp. announced that the company's recently launched Gummy Bear products are growing in popularity among Chinese children. The company has entered into a two-year distribution contract with Hangzhou Rong Sen Food Co. Ltd. ('Rong Sen'). Rong Sen will distribute Niusules's Gummy Bears and PlantFusion protein products in Century Lianhua Supermarket, Carrefour, Trust Mart and CRV (China Resources Vanguard) Mart in Zhejiang Province. Accounting to Rong Sen's estimates, the order value is expected to reach $5.0 million in the calendar year 2010. Rong Sen will also work with Niusule to market, display and manage promotional activities for the Company's products and expand Niusule's retail outlets to 36 by the end of 2009 and 100 by the end of 2010 in Zhejiang Province. The retail price of Niusule's products will be set by Rong Sen in accordance with Niusule's guidelines. Niusule and Rong Sen will work together to increase Niusule's market share in markets covered by Rong Sen, including Ningbo, Wenzhou, and Shaoxing.
NIUS Competitors
| Company | Last | Change | |
| No competitor information is available for NIUS. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | NIUS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 240.4x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
NIUS |
||
|
More Recent News About Niusule Biotech Corp.
More news for NIUS
Niusule Gummy Bears Continue Expanding Market Share in China
MONROVIA, Calif. and HANGZHOU, China, Nov. 17 /PRNewswire-FirstCall/ -- Niusule Biotech Corp. ("Niusule" or the "Company") (OTC Bulletin Board: NIUS - News), a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced that the Company's recently launched Gummy Bear products are growing in popularity among Chinese children. The Company has entered into a two-year distribution contract with Hangzhou Rong Sen Food Co., Ltd ("Rong Sen"), a leading distributor in Zhejiang Province, China. Rong Sen will distribute Niusules's Gummy Bears and PlantFusion protein products in Century Lianhua Supermarket, Carrefour, Trust Mart and CRV (China Resources Vanguard) Mart in Zhejiang Province. Accounting to Rong Sen's estimates, the order value is expected to reach $5.0 million in the calendar year 2010. Rong Sen will also work with Niusule to market, display and manage promotional activities for the Company's products and expand Niusule's retail outlets to 36 by the end of 2009 and 100 by the end of 2010 in Zhejiang ProvinceThe retail price of Niusule's products will be set by Rong Sen in accordance with Niusule's guidelines. Niusule and Rong Sen will work together to increase Niusule's market share in markets covered by Rong Sen, including Ningbo, Wenzhou, and Shaoxing....Click here to read the whole Article (external link)
NIUSULE BIOTECH CORP. Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis or Plan of Operation Forward-looking statements The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and the related notes thereto included elsewhere in this quarterly report on Form 10-Q. This quarterly report on Form 10-Q contains certain forward-looking statements and our future operating results could differ materially from those discussed herein. Certain statements contained in this discussion, including, without limitation, statements containing the words "believes", "anticipates," "expects" and the like, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). However, as we issue "penny stock," as such term is defined in Rule 3a51-1 promulgated under the Exchange Act, we are ineligible to rely on these safe harbor provisions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions of the forward-looking statements contained herein to reflect future events or developments. Overview Due to the economic and health food market conditions in China in 2008, we have adjusted our strategy in 2009 and have decided to refocus our short-term business plan to meet what we perceive as the urgent need to provide high quality health food to Chinese people. We have formed a new wholly-o...Click here to read the whole Article (external link)
Niusule Announces Key Additions to Management Team
MONROVIA, Calif. and HANGZHOU, China, Nov. 13 /PRNewswire-FirstCall/ -- Niusule Biotech Corp. ("Niusule" or the "Company") (OTC Bulletin Board: NIUS - News), a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced that Mr. Ping (Vince) Huang was named the Company's chief financial officer on November 6, 2009. Previously, Ms. Qinghua Hu, the Company's chief executive officer, also served as Niusule's CFO. The Company also retained Mr. Pei Pei as chief marketing officer of Niusule Bioengineering (Hangzhou) Co. Ltd. (Niusule Bioengineering), the Company's subsidiary in China. Mr. Huang's work experience includes key positions in investment banking, consulting, and business development. He most recently served as an investment consultant for PIEPS, an affiliate of Gemstong Capital, where he initiated and managed qualitative and quantitative analysis for buyout execution. Mr. Huang also worked on the University of Alabama-Birmingham's life-science entrepreneurship program, where he was responsible for analysis and market research related to the commercialization of intellectual property. Prior to that, Mr. Huang was a business analyst for Beijing Kawin Biotech Co., Ltd., coordinating regulatory approvals for manufacturing and control processes. He holds a Bachelo...Click here to read the whole Article (external link)
NIUSULE BIOTECH CORP. Files SEC form 8-K, Change in Directors or Principal Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 6, 2009, we formally signed an employment agreement with Ping Huang, age 30, as our CFO. Date From July 2009 to October 2009, he was a consultant to PIEPS, Inc. an Investment Advisory firm. Between July 2002 and July 2009, he was a student. From August 2001 to July 2002, he was Business Analyst for Beijing Kawin Biotechnology Co. He received a Ph.D./University of Alabama at Birmingham/Aug. 2002-Aug. 2007 and an M.B.A/ University of California, Los Angeles/ Sep.2007-Jun. 2009. In November 2009, we also retained Pei Pei, age 33, as Chief Marketing Officer of Niusule Bioengineering (Hangzhou) Co. Ltd., our China subsidiary. From May 2006 to December 2008, he was Marketing Manager of Zhejiang at Shanghai Longbin Biotechnology Co.,Ltd., a Pharmaceutical/bioengineering company. From February 2004 to May 2006, he was Manager of Zhejiang Branch, Beijing Sinceretime Pharmaceutical Company, a Pharmaceutical/bioengineering company. From September 2001 to December 2003, he was Sales Director of Shanghai Asia Pioneer Pharmaceutical Co., Ltd., a Pharmaceutical/bioengineering company. He has a college degree from China University of Geosciences. In November 2009, Guojun Huang resigned as Manager of our China subsidiary. Legal Proceedings Neither Ping Huang nor Pei Pei has not been involved in the last five years in any of the following: · Any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; · Any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); · Being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any...Click here to read the whole Article (external link)
NIUSULE BIOTECH CORP. Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
Niusule Enters into Long-Term Partnership Agreement with US Manufacturer
MONROVIA, Calif. and HANGZHOU, China, Oct. 16 /PRNewswire-FirstCall/ -- Niusule Biotech Corp. ("Niusule" or the "Company") (OTC Bulletin Board: NIUS - News), a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced that the Company has entered into a long-term partnership agreement ("agreement") with a leading US-manufacturer of enhanced confectionery products on October 6, 2009. "We are pleased to announce that we have entered into a supply agreement with a reputed nutritional supplement manufacturer in the U.S.," commented Ms. Qinghua Hu, CEO and CFO of Niusule Biotech Corp. "We believe securing a reliable and stable supply of high-quality products is an important step, especially in light of our recent expansion into China and the growing demand for gummy bears and other nutritional products in the Chinese market. We are excited about this opportunity and are confident in our ability to further expand our business and increase profitability."About Niusule Biotech Corp. Niusule is engaged in the business of manufacturing, marketing and selling health food and related products. The Company manufactures mature health food products, including PlantFusion and Gummy Bears, in the United States and markets and distributes these products to C...Click here to read the whole Article (external link)
NIUSULE BIOTECH CORP. Files SEC form 10-K, Annual Report
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and the related notes thereto included elsewhere in this registration statement. This registration statement contains certain forward-looking statements and our future operating results could differ materially from those discussed herein. Certain statements contained in this discussion, including, without limitation, statements containing the words "believes", "anticipates," "expects" and the like, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). However, as we will issue "penny stock," as such term is defined in Rule 3a51-1 promulgated under the Exchange Act, we are ineligible to rely on these safe harbor provisions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions of the forward-looking statements contained herein to reflect future events or developments. Overview Due to the economic and health food market conditions in China in 2008, we have adjusted our strategy in 2009 and have decided to refocus our short-term business plan to meet what we perceive as the urgent need to provide high quality health food to Chinese people. We have formed a new wholly-owned sub...Click here to read the whole Article (external link)
NIUSULE BIOTECH CORP. Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis or Plan of Operation Forward-looking statements The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and the related notes thereto included elsewhere in this quarterly report on Form 10-Q. This quarterly report on Form 10-Q contains certain forward-looking statements and our future operating results could differ materially from those discussed herein. Certain statements contained in this discussion, including, without limitation, statements containing the words "believes", "anticipates," "expects" and the like, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). However, as we issue "penny stock," as such term is defined in Rule 3a51-1 promulgated under the Exchange Act, we are ineligible to rely on these safe harbor provisions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions of the forward-looking statements contained herein to reflect future events or developments. Overview Due to recent economic and health food market conditions in China, we have decided to refocus our short-term business plan to meet what we perceive as the urgent need to provide high quality health food to Chinese people. We have formed a new wholly-owned subsidiary, Niusule Bioengineering (Han...Click here to read the whole Article (external link)
Would you like to leave a comment about Niusule Biotech Corp. NIUS/NIUS.OB
Find out what social network information about Niusule Biotech Corp. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Niusule Biotech Corp. there is more great information available at Realpennies.com